Vertrix Wealth Management LLC Invests $650,000 in Astrazeneca Plc $AZN

Vertrix Wealth Management LLC bought a new stake in Astrazeneca Plc (NYSE:AZN) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,297 shares of the company’s stock, valued at approximately $650,000.

Other large investors also recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after buying an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC increased its position in Astrazeneca by 2.1% during the 4th quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock worth $3,791,051,000 after buying an additional 438,709 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Astrazeneca by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 20,157,744 shares of the company’s stock worth $3,537,684,000 after buying an additional 445,014 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Astrazeneca by 3.2% during the fourth quarter. Morgan Stanley now owns 13,878,726 shares of the company’s stock worth $2,435,716,000 after buying an additional 432,939 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Astrazeneca by 9.4% in the third quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock valued at $521,517,000 after acquiring an additional 582,183 shares during the period. Institutional investors own 20.35% of the company’s stock.

More Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca’s cancer drug Enhertu won a new EU approval for HER2-positive solid tumors, its sixth EU indication, which could expand sales potential and support future revenue growth. AstraZeneca’s Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
• Positive Sentiment: Several major brokers reiterated buy ratings on AZN, including Goldman Sachs, Bank of America, and JPMorgan, signaling continued analyst confidence in the stock. Goldman Sachs Reaffirms Buy Rating
• Positive Sentiment: Erste Group raised its FY2026 EPS estimate for AstraZeneca, suggesting expectations for stronger earnings than previously forecast.
• Neutral Sentiment: Zacks highlighted AZN as a strong momentum stock and compared it with Illumina, reinforcing that the shares remain on investors’ radar, but without a direct new catalyst. Here’s Why Astrazeneca (AZN) is a Strong Momentum Stock
• Negative Sentiment: Despite the positive company-specific news, AZN still traded lower as broader market weakness and a conflicting sell rating from Deutsche Bank likely weighed on sentiment. Deutsche Bank Sell Rating

Astrazeneca Stock Down 3.0%

Shares of NYSE AZN opened at $183.99 on Thursday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca Plc has a 52 week low of $137.23 and a 52 week high of $212.71. The stock has a market capitalization of $285.35 billion, a P/E ratio of 27.63, a PEG ratio of 1.50 and a beta of 0.24. The stock’s fifty day moving average is $183.91 and its 200 day moving average is $187.58.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Sell-side analysts forecast that Astrazeneca Plc will post 10.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

AZN has been the topic of several research reports. UBS Group restated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday. Weiss Ratings cut shares of Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Fourteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.